Infections by Candida species are a high-impact problem in public
health due to their wide incidence in hospitalized patients. The goal of this study
was to evaluate frequency, susceptibility to antifungals, and genetic polymorphism of
Candida species isolated from clinical specimens of hospitalized
patients. The Candida isolates included in this study were obtained
from blood cultures, abdominal fluids, and central venous catheters (CVC) of
hospitalized patients at the Clinical Hospital of the Federal University of
Uberlândia during the period of July 2010 - June 2011. Susceptibility tests were
conducted by the broth microdilution method. The RAPD-PCR tests used employed
initiator oligonucleotides OPA09, OPB11, and OPE06. Of the 63
Candida isolates, 18 (28.5%) were C. albicans,
20 (31.7%) were C. parapsilosis complex species, 14 (22.2%)
C. tropicalis, four (6.4%) C. glabrata, four
(6.4%) C. krusei, two (3.3%) C. kefyr, and one
(1.6%) C. lusitaniae. In vitro resistance to
amphotericin B was observed in 12.7% of isolates. In vitroresistance
to azoles was not detected, except for C. krusei. The two primers,
OPA09 and OPB11, were able to distinguish different species. Isolates of C.
albicans and C. parapsilosis complex species presented
six and five clusters, respectively, with the OPA09 marker by RAPD-PCR, showing the
genetic variability of the isolates of those species. It was concluded that members
of the C. parapsilosis complex were the most frequent species found,
and most isolates were susceptible to the antifungals amphotericin B, flucozanole,
and itraconazole. High genetic polymorphisms were observed for isolates of C.
albicans and C. parapsilosis complex species, mainly
with the OPA09 marker.